# Drug-Induced Parkinsonism: A Structured, Mechanism-Informed Approach to Identification and Management

**Authors:** Beatriz De Faria Sousa, Juan B Espinosa

PMC · DOI: 10.7759/cureus.98340 · Cureus · 2025-12-02

## TL;DR

Drug-induced parkinsonism is a reversible condition often mistaken for Parkinson's disease, caused by certain medications and supplements, and can be managed by identifying and stopping the causative agent.

## Contribution

A structured, mechanism-informed three-step approach for identifying and managing drug-induced parkinsonism is proposed.

## Key findings

- DIP accounts for 15-20% of secondary parkinsonism, more common in older adults and women.
- Dopamine transporter imaging helps distinguish DIP from neurodegenerative parkinsonism.
- Symptoms often resolve within six to 12 months after stopping the causative drug.

## Abstract

Drug-induced parkinsonism (DIP) is an underrecognized form of secondary parkinsonism that can mimic idiopathic Parkinson’s disease yet is largely reversible. While the use of first-generation antipsychotics has declined, additional agents, including valproate, cyclosporine, vesicular monoamine transporter 2 inhibitors, and Rauwolfia serpentina-based herbal supplements, have emerged as notable contributors. This narrative review synthesizes epidemiologic, mechanistic, and clinical data from 2009 to 2025 to provide a structured, mechanism-informed approach for clinicians. Across studies, DIP accounted for roughly 15-20% of secondary parkinsonism, disproportionately affecting older adults and women. Functional imaging with dopamine transporter single-photon emission computed tomography typically demonstrates preserved striatal uptake, aiding differentiation from neurodegenerative parkinsonism. Recovery usually occurs within six to 12 months of discontinuing the offending agent, though a minority may experience persistent symptoms. The proposed three-step approach emphasizes comprehensive medication and supplement review, recognition of characteristic clinical patterns, and timely withdrawal with follow-up to confirm reversibility. This framework supports safer prescribing practices, reinforces clinician education, and enhances detection of this preventable condition.

## Linked entities

- **Chemicals:** valproate (PubChem CID 3549980), cyclosporine (PubChem CID 5284373)
- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** SLC6A3 (solute carrier family 6 member 3) [NCBI Gene 6531] {aka DAT, DAT1, PKDYS, PKDYS1}
- **Diseases:** idiopathic Parkinson's disease (MESH:D010300), DIP (MESH:D010302), neurodegenerative parkinsonism (MESH:D019636)
- **Chemicals:** vesicular monoamine transporter 2 inhibitors (-), valproate (MESH:D014635), cyclosporine (MESH:D016572)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12757197/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12757197/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12757197/full.md

---
Source: https://tomesphere.com/paper/PMC12757197